SOUTH KOREA PERSPECTIVE

Seoul plays an unexpected role in this outbreak: Jean Kaseya, director general of Africa CDC, is currently in South Korea to follow ongoing clinical trials, and he has requested that Professor Jean-Jacques Muyembe be associated with combined trials against Bundibugyo. Korea Times reveals this movement, but it is Korea Times that draws the financial threads in two complementary articles. The first details the $60 million allocated by CEPI to Moderna and two other groups to develop vaccines against Bundibugyo. The second announces an emergency meeting of European health ministers on Friday at the initiative of the Cypriot presidency.

Korea Times details the mechanics of the three candidates with notable financial precision: $50M for Moderna on its mRNA platform inherited from Covid, $8.6M for Oxford / Serum Institute of India on the ChAdOx1 platform, $3.2M for IAVI on the rVSV platform — the same as that of the already approved Ervebo vaccine for the Zaire strain. Richard Hatchett is quoted: 'Each day counts in the race against this deadly disease.' The daily adds a detail that few other media outlets relay: Oxford and Serum demonstrated last year, during the Rift Valley fever outbreak in Mauritania and Senegal, that they could produce doses ready for trials in six weeks, much faster than the usual schedules.

The Korean singularity lies in this global accounting. Korea Times mentions that Gavi has engaged up to $50 million more on Friday, and that the World Bank's Pandemic Fund has announced up to $220.6 million in subsidies. Total cumulative: over $330 million for the Bundibugyo vaccine response in just a few days. For a country that wants to make Korean bioproduction a showcase industry — Samsung Biologics, SK bioscience, Celltrion — these figures are not decorative. They outline a market. The coverage is strictly factual, without a geopolitical angle, but it says what interests Seoul: global health is now a sector of export, and South Korea wants to be in it.